3 assets in Keratoacanthoma

Therapeutic assets addressing Keratoacanthoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Keratoacanthoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Keratoacanthoma	National Cancer Institute (NCI)	P2	CCC (53)
L19IL2/L19TNF Keratoacanthoma	Philogen S.p.A.	P2	NR ()